• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Basilea Pharmaceutica - Articles and news items

isavuconazole

New Managed Access programme for isavuconazole

Industry news / 9 June 2016 / Victoria White, Digital Content Producer

The programme will enable patients with serious fungal infections in EU states where the treatment is not yet commercially available to access isavuconazole…

mucormycosis

Study data published for Cresemba in patients with mucormycosis

Industry news / 9 March 2016 / Victoria White

Cresemba (isavuconazonium sulfate) is an azole antifungal indicated for patients 18 years of age and older for the treatment of invasive aspergillosis and invasive mucormycosis…

isavuconazole

EC maintains orphan drug designation for Basilea’s isavuconazole

Industry news / 23 October 2015 / Victoria White

Isavuconazole will benefit from ten years of market exclusivity associated with orphan medicinal product status in the European Union…

Zevtera

Hikma signs exclusive agreement for Basilea’s Zevtera

Industry news / 15 October 2015 / Victoria White

Under the terms of the agreement, Hikma will have the exclusive rights to register, distribute and market Zevtera in all its Middle Eastern and North African markets…

isavuconazole

CHMP recommends approval of isavuconazole in the EU

Industry news / 27 July 2015 / Victoria White

CHMP has adopted a positive opinion recommending the approval of isavuconazole for the treatment of invasive aspergillosis and mucormycosis…

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +